Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY009212A in moderate to severe active ulcerative colitis
CTR20253115Phase 2Active
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MY009212A in autoimmune colitis, sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
MY009212A
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20253115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253115.